Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CYTK NASDAQ:NUVL NASDAQ:RNA OTCMKTS:TRUU On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYTKCytokinetics$51.13-4.1%$39.45$29.31▼$59.39$6.12B0.622.60 million shs1.90 million shsNUVLNuvalent$80.47-2.1%$78.68$55.53▼$113.51$5.80B1.29391,814 shs405,266 shsRNAAvidity Biosciences$44.74+9.0%$40.89$21.51▼$56.00$5.28B0.992.90 million shs12.96 million shsTRUUTrue Drinks$0.30-4.5%$0.17$0.00▼$0.08$1.51B10.91.01 million shs359,971 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYTKCytokinetics0.00%-3.55%+32.05%+48.72%-4.91%NUVLNuvalent0.00%-0.52%+4.78%+2.85%-6.03%RNAAvidity Biosciences0.00%-11.16%-2.89%+42.62%+10.36%TRUUTrue Drinks-4.52%+6.67%+78.82%+203.39%+245.45%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYTKCytokinetics$51.13-4.1%$39.45$29.31▼$59.39$6.12B0.622.60 million shs1.90 million shsNUVLNuvalent$80.47-2.1%$78.68$55.53▼$113.51$5.80B1.29391,814 shs405,266 shsRNAAvidity Biosciences$44.74+9.0%$40.89$21.51▼$56.00$5.28B0.992.90 million shs12.96 million shsTRUUTrue Drinks$0.30-4.5%$0.17$0.00▼$0.08$1.51B10.91.01 million shs359,971 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYTKCytokinetics0.00%-3.55%+32.05%+48.72%-4.91%NUVLNuvalent0.00%-0.52%+4.78%+2.85%-6.03%RNAAvidity Biosciences0.00%-11.16%-2.89%+42.62%+10.36%TRUUTrue Drinks-4.52%+6.67%+78.82%+203.39%+245.45%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYTKCytokinetics 2.87Moderate Buy$75.3847.44% UpsideNUVLNuvalent 3.08Buy$120.9150.25% UpsideRNAAvidity Biosciences 3.06Buy$68.3352.73% UpsideTRUUTrue Drinks 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest TRUU, CYTK, RNA, and NUVL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/12/2025RNAAvidity BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$68.00 ➝ $87.009/10/2025RNAAvidity BiosciencesNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$60.00 ➝ $65.009/10/2025RNAAvidity BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$75.009/8/2025NUVLNuvalentWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$115.009/4/2025NUVLNuvalentGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$122.009/3/2025CYTKCytokineticsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$53.00 ➝ $71.009/3/2025CYTKCytokineticsEvercore ISISubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$60.00 ➝ $80.009/2/2025NUVLNuvalentRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$105.009/2/2025CYTKCytokineticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy9/2/2025CYTKCytokineticsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$77.00 ➝ $84.009/2/2025CYTKCytokineticsStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$87.00 ➝ $96.00(Data available from 9/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYTKCytokinetics$85.74M71.36N/AN/A($1.15) per share-44.46NUVLNuvalentN/AN/AN/AN/A$14.99 per shareN/ARNAAvidity Biosciences$10.90M528.06N/AN/A$11.94 per share3.75TRUUTrue Drinks$1.95M775.23N/AN/A($0.03) per share-10.13Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYTKCytokinetics-$589.53M-$5.10N/AN/AN/A-707.17%N/A-45.52%11/5/2025 (Estimated)NUVLNuvalent-$260.76M-$4.90N/AN/AN/AN/A-32.58%-30.14%11/11/2025 (Estimated)RNAAvidity Biosciences-$322.30M-$3.56N/AN/AN/A-4,247.77%-33.45%-30.22%11/6/2025 (Estimated)TRUUTrue Drinks-$3.88M$0.0130.40∞N/A-255.80%N/A-165.86%N/ALatest TRUU, CYTK, RNA, and NUVL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025CYTKCytokinetics-$1.34-$1.12+$0.22-$1.12$1.95 million$66.77 million8/7/2025Q2 2025NUVLNuvalent-$1.27-$1.31-$0.04-$1.39N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCYTKCytokineticsN/AN/AN/AN/AN/ANUVLNuvalentN/AN/AN/AN/AN/ARNAAvidity BiosciencesN/AN/AN/AN/AN/ATRUUTrue DrinksN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYTKCytokineticsN/A6.766.76NUVLNuvalentN/A13.5713.57RNAAvidity BiosciencesN/A9.269.26TRUUTrue DrinksN/A0.01N/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYTKCytokineticsN/ANUVLNuvalent97.26%RNAAvidity BiosciencesN/ATRUUTrue DrinksN/AInsider OwnershipCompanyInsider OwnershipCYTKCytokinetics2.70%NUVLNuvalent10.20%RNAAvidity Biosciences3.83%TRUUTrue Drinks18.18%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCYTKCytokinetics250119.66 million116.43 millionOptionableNUVLNuvalent4072.11 million64.75 millionOptionableRNAAvidity Biosciences190128.65 million123.73 millionOptionableTRUUTrue Drinks404.97 billionN/ANot OptionableTRUU, CYTK, RNA, and NUVL HeadlinesRecent News About These CompaniesTrue Drinks (OTCMKTS:TRUU) Share Price Crosses Above 50-Day Moving Average - Here's What HappenedSeptember 8, 2025 | marketbeat.comTrue Drinks (OTCMKTS:TRUU) Stock Price Crosses Above Fifty Day Moving Average - Here's WhyAugust 31, 2025 | marketbeat.comBeer News: True Acts Of Aletruism / New “Indie Beer” CampaignNovember 13, 2024 | americancraftbeer.comAHow Much Alcohol Can You Drink a Week and Still Be Healthy?November 13, 2024 | msn.comStarbucks holiday menu: What's the healthiest drink? How much sugar, caffeine is in the seasonal beverages and other nutritional factsNovember 9, 2024 | msn.comCan You Drink Alcohol After Getting a COVID-19 Booster?October 29, 2024 | health.comHIt's True: Some Pizza Hut Locations Still Serve AlcoholOctober 22, 2024 | yahoo.comReview: True Story Finished BourbonOctober 21, 2024 | msn.comVitalizes Body and Mind.®October 4, 2024 | redbull.comR7UP confirms limited release of ‘most overdue’ soda flavor: ‘Dream come true’October 2, 2024 | msn.com‘Diabetes in a cup!’ Dunkin worker reveals most ‘absurd’ drink he’s ever made — here’s what’s in itSeptember 21, 2024 | nypost.comNSeattle’s True Loves Drop a Funky New SingleAugust 31, 2024 | msn.comCannabis Beverage of the Week: Nowadays stands out in a crowded field of THC drinksAugust 31, 2024 | msn.comThese alcoholic drinks can raise the risk of gout, a painful type of arthritisAugust 30, 2024 | nypost.comN14 Drinks You Should Think Twice About Ordering At A Bar, According To A Master MixologistAugust 29, 2024 | yahoo.com7 things you NEED to know about Prime Drinks (and the very different things the internet will tell you)August 25, 2024 | bbc.co.uk12 Unhealthiest Drinks You Should Think Twice About Ordering At A BarAugust 18, 2024 | msn.comTrue Loaf Bakery gets starter from two local bakersAugust 10, 2024 | msn.comPD TRUE : STREAM IT OR SKIP IT?August 6, 2024 | decider.comD10 Drinks People Fake Liking to Fit InAugust 5, 2024 | msn.com16 Best Summer Cocktails for a Hot Weather BuzzJuly 26, 2024 | esquire.comENew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesChevron Stock Outlook: Dividend Growth Meets InflationBy Chris Markoch | August 28, 20252 Powerful Forces Now Back Intel's TurnaroundBy Jeffrey Neal Johnson | August 20, 2025How a Superstore Strategy Fueled MINISO’s 20% Stock SurgeBy Jeffrey Neal Johnson | August 26, 2025Lyft's Billion-Dollar Signal: Why Wall Street Is Betting BigBy Jeffrey Neal Johnson | August 19, 2025Ubiquiti's 30% Jump: Why This Was a Turnaround, Not Just a TrendBy Jeffrey Neal Johnson | August 26, 2025TRUU, CYTK, RNA, and NUVL Company DescriptionsCytokinetics NASDAQ:CYTK$51.13 -2.19 (-4.11%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$52.30 +1.18 (+2.30%) As of 09/12/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.Nuvalent NASDAQ:NUVL$80.47 -1.75 (-2.13%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$80.50 +0.03 (+0.04%) As of 09/12/2025 05:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.Avidity Biosciences NASDAQ:RNA$44.74 +3.70 (+9.02%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$44.90 +0.16 (+0.35%) As of 09/12/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.True Drinks OTCMKTS:TRUU$0.30 -0.01 (-4.52%) As of 09/12/2025True Drinks Holdings, Inc. markets and distributes nutritional supplement drinks. The company sells Bazi All Natural Energy, a liquid nutritional supplement drink through drinkbazi.com. It also formulates products containing CBD; and produces and distributes vapor products in approximately 90 countries. The company was formerly known as True Drinks, Inc. and changed its name to True Drinks Holdings, Inc. in October 2012. True Drinks Holdings, Inc. was founded in 2008 and is headquartered in Irvine, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Football Season Is Here and DraftKings Stock Is Surging RH Stock Slides After Mixed Earnings and Tariff Concerns Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
